Placebo + PF-03654746
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Excessive Daytime Sleepiness
Conditions
Excessive Daytime Sleepiness, Narcolepsy
Trial Timeline
Nov 1, 2009 → Nov 1, 2010
NCT ID
NCT01006122About Placebo + PF-03654746
Placebo + PF-03654746 is a phase 2 stage product being developed by Pfizer for Excessive Daytime Sleepiness. The current trial status is completed. This product is registered under clinical trial identifier NCT01006122. Target conditions include Excessive Daytime Sleepiness, Narcolepsy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01006122 | Phase 2 | Completed |
Competing Products
8 competing products in Excessive Daytime Sleepiness
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| JZP-110 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Solriamfetol + Placebo | Axsome Therapeutics | Approved | 82 |
| Solriamfetol 150 MG + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol Oral Tablet + Placebo | Axsome Therapeutics | Approved | 82 |
| Fibrin Sealant Grifols + EVICEL | Grifols | Phase 3 | 74 |
| ORX142 Tablets | Centessa Pharmaceuticals | Phase 1 | 28 |
| VSF-173 | Vanda Pharmaceuticals | Phase 2 | 44 |